Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Invesco Galaxy Bitcoin ETF (BTCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Invesco Galaxy Bitcoin ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Invesco Galaxy Bitcoin ETF trades at $63.04. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Invesco Galaxy Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| BIO | BTCO | |
|---|---|---|
Market Cap | $9.39B | — |
Sector | Health | Crypto-linked |
52-Week High | $356.25 | $125.14 |
52-Week Low | $241.71 | $58.40 |
Enterprise Value | $9.14B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
BTCO stock trades at $64.60, up 0.86% today amid mixed technical signals. The overall technical picture shows bearish momentum with key support at $63 and resistance at $65. Financial ratios remain unavailable in current data, requiring fundamental verification through SEC filings.
Investment outlook hinges on forthcoming financial disclosures to assess valuation. Key risks include market volatility and competitive pressures. The stock's near-term direction will likely be driven by earnings results and institutional positioning updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Invesco Galaxy Bitcoin ETF
BTCO is a spot Bitcoin ETF that tracks the price of Bitcoin directly. It offers investors a regulated and convenient way to gain exposure to the digital currency through a traditional brokerage account without holding the asset.
Read more on BTCO →
